Gossamer Bio Inc (GOSS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $67.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gossamer Bio Inc (GOSS) Earnings: Report Dates and Results
Gossamer Bio (GOSS) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Gossamer Bio reported EPS of -$1.19, above the -$5.55 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GOSS has an expected report date of Mar 15, 2027.
GOSS Earnings Call
The latest GOSS earnings call transcript on file is labeled 2026Q1.
Read the 2026Q1 transcriptEarnings History
Of the 31 quarters below that had an estimate, GOSS beat 10, missed 16 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $38.43M, up 189.2% from $13.29M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.19 | -$5.55 | -$7.43 - $0.80 | +78.56% | Beat | N/A | 5 | 0 up, 0 down | Nov 10, 2026 | $38.43M |
| Jun 30, 2026 | -$0.20 | -$0.10 | -$0.24 - -$0.04 | -100.00% | Miss | N/A | 7 | 1 up, 1 down | Aug 13, 2026 | $9.24M |
| Mar 31, 2026 | -$0.20 | -$0.17 | -$0.25 - -$0.05 | -17.65% | Miss | N/A | 7 | N/A | May 18, 2026 | $16.95M |
| Dec 31, 2025 | -$0.21 | -$0.19 | -$0.25 - -$0.13 | -13.51% | Miss | N/A | 9 | 1 up, 3 down | Mar 17, 2026 | $13.80M |
| Sep 30, 2025 | -$0.21 | -$0.19 | -$0.22 - -$0.17 | -10.53% | Miss | N/A | 7 | 2 up, 4 down | Nov 5, 2025 | $13.29M |
| Jun 30, 2025 | -$0.17 | -$0.18 | -$0.20 - -$0.16 | +5.56% | Beat | -177.3% | 9 | 4 up, 1 down | Aug 5, 2025 | $11.49M |
| Mar 31, 2025 | -$0.16 | -$0.18 | -$0.22 - -$0.17 | +11.11% | Beat | N/A | 7 | 0 up, 0 down | May 15, 2025 | $9.89M |
| Dec 31, 2024 | -$0.15 | -$0.17 | -$0.21 - -$0.08 | +10.71% | Beat | N/A | 8 | 4 up, 3 down | Mar 13, 2025 | $9.38M |
| Sep 30, 2024 | -$0.14 | -$0.14 | -$0.22 - -$0.01 | 0.00% | In line | N/A | 10 | 0 up, 0 down | Nov 7, 2024 | $9.48M |
| Jun 30, 2024 | $0.22 | $0.27 | -$0.20 - $0.55 | -18.52% | Miss | N/A | 10 | 0 up, 0 down | Aug 12, 2024 | $95.84M |
| Mar 31, 2024 | -$0.19 | -$0.19 | -$0.23 - -$0.15 | 0.00% | In line | N/A | 9 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$0.21 | -$0.21 | -$0.29 - -$0.17 | 0.00% | In line | N/A | 8 | 0 up, 0 down | Mar 5, 2024 | $6.78M |
| Sep 30, 2023 | -$0.21 | -$0.27 | -$0.65 - -$0.18 | +22.22% | Beat | N/A | 10 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.45 | -$0.50 | -$0.60 - -$0.41 | +10.00% | Beat | N/A | 10 | 1 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$0.52 | -$0.54 | -$0.62 - -$0.41 | +3.70% | Beat | N/A | 10 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$0.59 | -$0.62 | -$0.67 - -$0.57 | +4.84% | Beat | N/A | 13 | 0 up, 0 down | Mar 17, 2023 | N/A |
| Sep 30, 2022 | -$0.65 | -$0.66 | -$0.84 - -$0.56 | +1.52% | Beat | N/A | 12 | 1 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$0.74 | -$0.69 | -$0.79 - -$0.44 | -7.25% | Miss | N/A | 9 | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$0.76 | -$0.76 | -$0.86 - -$0.69 | 0.00% | In line | N/A | 8 | 1 up, 0 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.74 | -$0.74 | -$0.82 - -$0.64 | 0.00% | In line | N/A | 6 | N/A | Mar 3, 2022 | N/A |
| Sep 30, 2021 | -$0.80 | -$0.77 | -$0.82 - -$0.74 | -3.90% | Miss | N/A | 5 | 0 up, 0 down | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$0.80 | -$0.76 | -$0.79 - -$0.73 | -5.26% | Miss | N/A | 4 | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$0.78 | -$0.74 | -$0.82 - -$0.70 | -5.41% | Miss | N/A | 4 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.88 | -$0.79 | -$0.92 - -$0.65 | -11.39% | Miss | N/A | 6 | N/A | Feb 25, 2021 | N/A |
| Sep 30, 2020 | -$0.80 | -$0.85 | -$0.95 - -$0.75 | +5.88% | Beat | N/A | 6 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$1.00 | -$0.86 | -$1.07 - -$0.70 | -16.28% | Miss | N/A | 6 | N/A | Aug 11, 2020 | N/A |
| Mar 31, 2020 | -$0.87 | -$0.75 | -$0.85 - -$0.75 | -16.00% | Miss | N/A | 5 | N/A | May 12, 2020 | N/A |
| Dec 31, 2019 | -$0.89 | -$0.86 | -$1.07 - -$0.73 | -3.49% | Miss | N/A | 6 | N/A | Mar 24, 2020 | N/A |
| Sep 30, 2019 | -$0.80 | -$0.68 | -$0.71 - -$0.68 | -17.65% | Miss | N/A | 2 | N/A | Nov 12, 2019 | N/A |
| Jun 30, 2019 | -$0.74 | -$0.43 | N/A | -72.09% | Miss | N/A | 1 | N/A | Aug 8, 2019 | N/A |
| Mar 31, 2019 | -$0.90 | -$0.58 | N/A | -55.17% | Miss | N/A | 2 | N/A | May 14, 2019 | N/A |
| Dec 31, 2018 | -$18.23 | -$1.00 | -$1.45 - -$0.17 | N/A | N/A | N/A | 3 | N/A | Feb 12, 2019 | N/A |
| Sep 30, 2018 | -$0.93 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 11, 2018 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.75, after -$0.26 the year before. It was -$19.16 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.75 | N/A |
| Dec 31, 2024 | -$0.26 | N/A |
| Dec 31, 2023 | -$1.39 | N/A |
| Dec 31, 2022 | -$2.74 | N/A |
| Dec 31, 2021 | -$3.12 | N/A |
| Dec 31, 2020 | -$3.55 | N/A |
| Dec 31, 2019 | -$3.33 | N/A |
| Dec 31, 2018 | -$19.16 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,500 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q1 | Mar 31, 2026 | 5,512 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,654 | 14 |
2026Q1 Earnings Call
Opening remarks
Bryan Giraudo Chief Operating Officer and Chief Financial Officer Good morning, and thank you for joining us. Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements, including statements regarding our regulatory plans, potential NDA submission and approval timing, commercialization, expectations, cash runway, capital structure and the potential therapeutic benefit and future developments of seralutinib. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and today's press release for discussions of these risks. We undertake no obligation to update these forward-looking statements, except as required by law. We are very excited this morning to have on our call today, Faheem Hasnain, Caryn Peterson, Dr. Rob Roscigno. Additionally, we have Dr. Jean-Marie Bruey, Dr. Rainer Zimmermann, Dr. Megan Flynn, Dr. Robin Osterhout; and Bob Smith, our Chief Commercial Officer, to speak about our exciting results this morning. Today, we plan to cover 3 topics: First, a regulatory update, including our Type B pre-NDA meeting; Secondly, we will discuss results from our PROSERA CT FRI substudy; and third, an update on our capital structure, including the convertible note exchange. Our financial results for the first quarter of 2026 are included in this press release, and I will come back to briefly discuss these at the end of the call. With that overview, let me hand it over to Faheem to discuss our recent progress. Faheem?
Faheem Hasnain Chief Executive Officer Yes. Thanks, Bryan, and good morning, everybody. In February, we reported top line results from PROSERA, our Phase III study of seralutinib in patients with PAH. At a high level, PROSERA showed a clinically meaningful placebo-adjusted improvement of 13.3 meters in 6-minute walk distance at week 24, with patients on seralutinib improving 28.2 meters from baseline versus 13.5 meters on placebo and a p-value of 0.032. That p-value met the traditional 0.05 threshold for statistical significance, but it did not meet the prespecified 0.025 alpha threshold. At the same time, all 4 key secondary endpoints favored seralutinib over placebo, and we saw a stronger effect in the prespecified risk-enriched subgroup. Taken together, we believe the totality of the PROSERA data supports a real and clinically meaningful treatment signal. Now since the PROSERA top line readout, we've been focused on 3 work streams in parallel. First, we engaged with the FDA on the path forward for seralutinib. That process advanced from the previously disclosed Type C meeting to a Type B pre-NDA meeting, which is the most formal pre-submission meeting type. The meeting has been confirmed as in person and the briefing book has been submitted. Caryn will cover that in more detail shortly.
Frequently Asked Questions About GOSS
When is Gossamer Bio's next earnings date?
Gossamer Bio's next earnings report is expected for Mar 15, 2027.
Did GOSS beat earnings estimates last quarter?
Yes. Gossamer Bio reported EPS of -$1.19 for the quarter ended Sep 30, 2026, above the -$5.55 estimate, a 78.56% surprise.
What EPS do analysts expect from GOSS next quarter?
The consensus EPS estimate for Gossamer Bio for the quarter ending Dec 31, 2026 is -$3.23 from 9 analysts, with estimates from -$6.13 to -$1.60.
How often does GOSS beat earnings estimates?
Gossamer Bio beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -4.47%.
GOSS pages: Overview, Earnings, Forecast, Financials, Competitors